University of Worcester Worcester Research and Publications
 
  USER PANEL:
  ABOUT THE COLLECTION:
  CONTACT DETAILS:

Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer

Häntschel, M. ORCID: https://orcid.org/0000-0002-0610-1959, Niebling, J., Häring, A., Häring, M-F., Groß, T., Horger, M., Riessen, R., Haap, M., Lewis, Richard, Böckeler, M. and Hetzel, J. (2020) Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer. Thoracic cancer, 11 (7). pp. 2044-2047. ISSN 1759-7714

[img]
Preview
Text (Version of Record)
Lewis-2020-Life-threatening-pneumonitis-after-first-line-treatment-with-osimertinib-for-primary-T790M-mutated-non-small-cell-lung-cancer.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (636kB) | Preview

Abstract

Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced, EGFR-mutated non-small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority of patients, severe and even life-threatening side effects have been reported. TKI-induced interstitial lung disease (ILD) has been reported for single cases in modest severity, predominantly in EGFR-TKI pretreated patients. Here, we report a case of successful stabilization of a life-threatening ILD in a de novo T790M mutated NSCLC during first-line treatment with osimertinib. As osimertinib will be used more often in many EGFR-positive NSCLC patients in the future, this potentially life-threatening side effect should receive special attention, especially in first-line treatment

Item Type: Article
Additional Information:

The full-text of the online published article can be accessed via the official URL. This is an open access article under the CC-BY 4.0 licence (https://creativecommons.org/licenses/by/4.0/)

Uncontrolled Discrete Keywords: epithelial growth factor receptor, interstitial lung disease, pneumonitis, side effect, tyrosine kinase inhibitor
Subjects: R Medicine > R Medicine (General)
Divisions: College of Health, Life and Environmental Sciences > School of Science and the Environment
Related URLs:
Copyright Info: Open access article
SWORD Depositor: Prof. Pub Router
Depositing User: Karen Veitch
Date Deposited: 20 May 2020 12:52
Last Modified: 08 Jul 2020 12:02
URI: https://eprints.worc.ac.uk/id/eprint/9447

Actions (login required)

View Item View Item
 
     
Worcester Research and Publications is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.